STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3551 by analyst upside · 2026-06-27
CORT
Corcept Therapeutics Incorporated
Healthcare · Market Cap $9B · P/E 249.5x
ANALYST PRICE TARGET
+0.8%
implied upside to consensus target
Current Price $87.32
Consensus Target $88.0
Bull Target $135.0
Bear Target $50.0
Analysts Covering 5
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
2
Hold
2
Sell
0
52-Week Low $28.66
52-Week High $91.0
YTD Return +128.6%
FUNDAMENTALS
Market Cap $9B
P/E Ratio (TTM) 249.5x
Forward P/E 35.0x
EPS (TTM) $0.35
PEG Ratio 0.81
Dividend Yield N/A
Revenue (TTM) $769M
Profit Margin 6.2%
52-WEEK RANGE
52-Week Low $28.66
52-Week High $91.0
Current Price $87.32
Bear Target $50.0
Bull Target $135.0
● Now $87.32 ● Target $88.0
TRADING DATA
Avg Volume 1.2M
YTD Return +128.6%
Analyst Count 5
Consensus Buy
Upside to Target +0.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Corcept Therapeutics Incorporated (CORT) is currently trading at $87.32 with a Wall Street consensus price target of $88.0, implying potential upside of 0.8% over the next 12 months. 5 analysts currently cover CORT, with a consensus rating of Buy — 60% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $135.0, while the most cautious has a target of $50.0.

CORT operates in the Healthcare sector with a market capitalisation of $9B. The stock is up 128.6% year-to-date and is currently trading near the upper end of its 52-week range of $28.66 – $91.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CORT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-05-28 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-05-28 31% win rate (48 calls)
UBS ↑ Upgrade
Neutral → Buy 2026-05-13 33% win rate (6 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-05-04 31% win rate (48 calls)
Piper Sandler — Reiterated
Overweight → Overweight 2026-05-01 14% win rate (7 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-03-26 Building track record
Wolfe Research ↑ Upgrade
Underperform → Peer Perform 2026-03-26 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-25 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →